<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272102</url>
  </required_header>
  <id_info>
    <org_study_id>HD-OCT-GCA-2010-1</org_study_id>
    <nct_id>NCT01272102</nct_id>
  </id_info>
  <brief_title>Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma</brief_title>
  <official_title>Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DataMed Devices Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Carl Zeiss Meditec, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the area under the Receiver Operator Characteristic Curve (AUC) for the Ganglion
      Cell Analysis (GCA) average thickness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the area under the Receiver Operator Characteristic Curve (AUC) for the
      following GCA parameters:

        1. Minimum thickness

        2. Supero-temporal thickness

        3. Superior thickness

        4. Supero-nasal thickness

        5. Infero-temporal thickness

        6. Inferior thickness

        7. Infero-nasal thickness
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the area under the Receiver Operator Characteristic Curve (AUC) for the GCA average thickness, and 7 more GCA parameters.</measure>
    <time_frame>Study was released before December 1, 2012</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">119</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>subjects with glaucoma</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 40 years or older

          -  Diagnosed to have glaucoma by the Principal Investigator or co-investigator

          -  Able and willing to make the required study visits

          -  Able and willing to give consent and follow study instructions

        Exclusion Criteria:

        Ophthalmic:

          -  Best corrected visual acuity in either eye worse than 20/40 on a Snellen chart or on a
             Snellen equivalent acuity chart.

          -  Refractive error outside -12.00D to +8.00D spherical range or &gt;-3.00D cylinder.

          -  Previous vitreoretinal surgery in study eye.

          -  Vitreoretinal traction or epiretinal membrane in the study eye.

          -  Any active infection of anterior or posterior segments.

          -  Evidence of diabetic retinopathy, diabetic macular edema, or other vitreoretinal
             disease in the study eye upon dilated examination, or upon evaluation of retinal
             photos.

        Systemic:

          -  History of diabetes, leukemia, AIDS, uncontrolled systemic hypertension, dementia or
             multiple sclerosis.

          -  A life threatening or debilitating disease.

          -  Participation in any study involving a non-FDA approved investigational drug (IND)
             within the past month, or ongoing participation in a study with a non-FDA approved or
             cleared investigational device (IDE).

          -  Current or recent (within the past 14 days) use of an agent with photosensitizing
             properties by any route (e.g., Visudyne®, ciprofloxacin, Bactrim®, doxycycline, etc.).

          -  Concomitant use of hydrochloroquine and/or chloroquine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Budenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arvind Neelakantan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Associates of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Utah Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Eye Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Eye Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009 Dec;116(12):2305-14.e1-2. doi: 10.1016/j.ophtha.2009.05.025. Epub 2009 Sep 10.</citation>
    <PMID>19744726</PMID>
  </reference>
  <reference>
    <citation>Wang M, Hood DC, Cho JS, Ghadiali Q, De Moraes CG, Zhang X, Ritch R, Liebmann JM. Measurement of local retinal ganglion cell layer thickness in patients with glaucoma using frequency-domain optical coherence tomography. Arch Ophthalmol. 2009 Jul;127(7):875-81. doi: 10.1001/archophthalmol.2009.145. Erratum in: Arch Ophthalmol. 2010 Sep;128(9):1150. De Moraes, Gustavo V [corrected to De Moraes, Carlos Gustavo].</citation>
    <PMID>19597108</PMID>
  </reference>
  <reference>
    <citation>Zeimer R, Asrani S, Zou S, Quigley H, Jampel H. Quantitative detection of glaucomatous damage at the posterior pole by retinal thickness mapping. A pilot study. Ophthalmology. 1998 Feb;105(2):224-31.</citation>
    <PMID>9479279</PMID>
  </reference>
  <reference>
    <citation>Mori S, Hangai M, Sakamoto A, Yoshimura N. Spectral-domain optical coherence tomography measurement of macular volume for diagnosing glaucoma. J Glaucoma. 2010 Oct-Nov;19(8):528-34. doi: 10.1097/IJG.0b013e3181ca7acf.</citation>
    <PMID>20164794</PMID>
  </reference>
  <reference>
    <citation>Seong M, Sung KR, Choi EH, Kang SY, Cho JW, Um TW, Kim YJ, Park SB, Hong HE, Kook MS. Macular and peripapillary retinal nerve fiber layer measurements by spectral domain optical coherence tomography in normal-tension glaucoma. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1446-52. doi: 10.1167/iovs.09-4258. Epub 2009 Oct 15.</citation>
    <PMID>19834029</PMID>
  </reference>
  <reference>
    <citation>Kim NR, Lee ES, Seong GJ, Kim JH, An HG, Kim CY. Structure-function relationship and diagnostic value of macular ganglion cell complex measurement using Fourier-domain OCT in glaucoma. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4646-51. doi: 10.1167/iovs.09-5053. Epub 2010 Apr 30.</citation>
    <PMID>20435603</PMID>
  </reference>
  <reference>
    <citation>Hodapp E, Parrish RK II, Anderson DR. Clinical Decisions in Glaucoma. St. Louis, MO: Mosby; 1993:52- 61</citation>
  </reference>
  <reference>
    <citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837-45.</citation>
    <PMID>3203132</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

